Edith A. Perez

A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET).

E. Perez, T. Petit, M. Andersson, 2012 .

MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).

E. Perez, P. Ellis, C. Barrios, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.